Literature DB >> 20695522

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.

Roberto T Bossi1, M Beatrice Saccardo, Elena Ardini, Maria Menichincheri, Luisa Rusconi, Paola Magnaghi, Paolo Orsini, Nilla Avanzi, Andrea Lombardi Borgia, Marcella Nesi, Tiziano Bandiera, Gianpaolo Fogliatto, Jay A Bertrand.   

Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-molecule inhibitors for the treatment of ALK-positive malignancies. Here, we present the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684. Analysis of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors. In addition, the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded beta-sheet. Finally, mapping of the activating mutations associated with neuroblastoma onto our structures may explain the roles these residues have in the activation process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695522     DOI: 10.1021/bi1005514

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  53 in total

1.  Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Authors:  Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

2.  The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding.

Authors:  Eduard R Felder; Alessandra Badari; Teresa Disingrini; Sergio Mantegani; Christian Orrenius; Nilla Avanzi; Antonella Isacchi; Barbara Salom
Journal:  Mol Divers       Date:  2012-02-15       Impact factor: 2.943

Review 3.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

4.  ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Authors:  Johannes M Heuckmann; Michael Hölzel; Martin L Sos; Stefanie Heynck; Hyatt Balke-Want; Mirjam Koker; Martin Peifer; Jonathan Weiss; Christine M Lovly; Christian Grütter; Daniel Rauh; William Pao; Roman K Thomas
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

5.  Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authors:  Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

6.  The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

Authors:  Takaaki Sasaki; Katsuhiro Okuda; Wei Zheng; James Butrynski; Marzia Capelletti; Liping Wang; Nathanael S Gray; Keith Wilner; James G Christensen; George Demetri; Geoffrey I Shapiro; Scott J Rodig; Michael J Eck; Pasi A Jänne
Journal:  Cancer Res       Date:  2010-10-28       Impact factor: 12.701

7.  Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.

Authors:  Gregory R Ott; Rabindranath Tripathy; Mangeng Cheng; Robert McHugh; Andrew V Anzalone; Ted L Underiner; Matthew A Curry; Matthew R Quail; Lihui Lu; Weihua Wan; Thelma S Angeles; Mark S Albom; Lisa D Aimone; Mark A Ator; Bruce A Ruggeri; Bruce D Dorsey
Journal:  ACS Med Chem Lett       Date:  2010-09-01       Impact factor: 4.345

8.  The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.

Authors:  Linda F Epstein; Hao Chen; Renee Emkey; Douglas A Whittington
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

Review 9.  Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.

Authors:  J de Castro-Carpeño; R Perona; C Belda-Iniesta
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

Review 10.  Pseudokinases from a structural perspective.

Authors:  Susan S Taylor; Andrey Shaw; Jiancheng Hu; Hiruy S Meharena; Alexandr Kornev
Journal:  Biochem Soc Trans       Date:  2013-08       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.